Evercore ISI raised the firm’s price target on BridgeBio (BBIO) to $125 from $100 and keeps an Outperform rating on the shares. As Attruby growth re-accelerates, the firm contends that the Street “still underappreciates” BridgeBio’s evolution into a four-product company.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio price target lowered to $81 from $83 at Oppenheimer
- BridgeBio Pharma: Clear Path to 2027 Profitability with Underappreciated Pipeline Upside
- BridgeBio: Robust Attruby Launch and Late-Stage Pipeline Support Buy Rating and Path to Sustainable Cash Generation
- BridgeBio reports Q4 EPS ($1.00), consensus (67c)
- BridgeBio off lows as traders discuss conference appearance